Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The spam is every hour. If the company was legit, they would put substantive tweets. Their website looks like it was created by a tech school drop out. Pitiful.
The funny thing is I can't discuss the stock on Twitter due to the rinse and repeat spam. It's like having a carnival barker luring you into the freak show at a third rate circus.
One of my dumb friends likes this company so I went on Twitter to check this company out and it looks like the company just has a feed full of paid spam. Pretty pathetic.
DRRX whew that's a stinker
Thanks for your reply
Dew, are you buying BMY on the dip?
How do you know that the stock may just not be desirable, hence the low market cap, versus the stock not discovered?
Bobby! What's the next pick??????
After doing a lot of dd, it's clear management execution has been superb. On track for European approval with Shire and sales ramping up for Onivyde in the USA. You can't ask for a better spec stock especially with FDA approved Onivyde meets an unmet need in pancreatic cancer treatment and has no competition. MACK has full rights in the USA as well.
The stock price is near 52 week lows and so I initiated a long position.
All we need is a time machine to cash in on this almanac of buyouts.
I was cynical as well but the bank loan tells me all I need to know that this company is on the level. Anybody that has received a bank loan knows the due diligence that the bank conducts to verify your assets, financial information, credit score etc. Long ABRW.
Perhaps it will be heading back to .60 with a few key PR's coming soon. Shhhhhhhhhh....
I'm expecting any minute a Clay Trader pump video on ABRW. Where is he?
I'm guessing this goes back to the pre BO rumor PR from the other day. The company needs to sell the product and stop the rumors.
Is it low fat?
Whatever punk!!!!
Yo mama let you suckle her milky bazooms with that filthy mouth?
Can't fix corrupt.com
www.frontloader.com
This might be a timber moment.
Lots of shorting today in CELG. Beware of vipers.
10:30 am a little birdy talked to me and said sell.
Where is Leo?
Awaiting VRTX open. Any thoughts on approval? Price seems to be the only issue?
Looks like Biogen isn't willing to give the $1 billion up front to AGTC like CELG will give the $1 billion up front JUNO. Maybe Dew can do the math lololololol
lol nice try
Is it a technical bottom or is it the lawsuits are under control, and the discontinuation of selling Chinese laminates ?
I'm jealous (if you know what I mean wink wink).
Maybe in another 10 years Dana Farber will come to a conclusion for a maximum tolerated dose for Kevitrin lol?
Assuming the story is maintained
Just smells like bs. The newest board member is suspect. Lots of red flags. I say this will be below a buck in 3 years or less.
11th cohort and seems like there arent AE'S. My guess is that it doesnt work. Just my opinion.
The status quo?
I'd be very careful with this company. Uli, or the company torpedoed a lot of investors. This is strictly a trading stock imo.
The pH for Kevetrin isn't know according to the the safety sheet. That's very reassuring.
Bob you are the man.
It needs to relax lol
ABBV woke up a sleeping giant with it's ESRX deal. All of these GILD deals prove that V-PAK is a much less desirable med. What PBM would want it, except if the price is super low? So GILD takes the hit on discounting but probably makes up for it with higher volume. Apparently ABBV is only interested in Medicaid/ESRX scripts. Wait until Humira sinks. The stock price will look good on them weeeeee!
China buying more iPhones than US
Tim Bradshaw in San Francisco
A customer tries out an Apple Inc. iPhone 6©Bloomberg
Apple is expected to say this week that it has sold more iPhones in China than on its home turf in the US for the first time last year, highlighting the shifting power balance of the smartphone market.
Analysts estimate that the US tech group reached the turning point in iPhone sales after expanding its presence in China last year via a deal with China Mobile, the country’s largest network operator, and after the release of the latest iPhone 6 in the country in October.
The iPhone’s growing market share in China comes as Samsung, the global market leader by smartphone volumes, has stumbled and the region has seen the rapid rise of low-cost challenger Xiaomi.
Tim Cook, chief executive, had said in 2013 that he expected China to eventually overtake the US as Apple’s single largest source of revenue. The iPhone already accounts for more than half of Apple’s total sales and an even larger share of its profits.
Analysts at UBS estimate that China accounted for 36 per cent of iPhone shipments in the most recent quarter, compared with 24 per cent for the US. During the same period last year, 29 per cent of units were sold in the US and 22 per cent were in China, UBS said.
“It’s already been a good year, building up to the climax of this quarter,” said Ben Bajarin, analyst at Creative Strategies, referring to Apple’s momentum in the world’s largest smartphone market. “It leads to a lot more optimism for China?.?.?.?Their potential headroom in China is higher than it is here [in the US].”
Mr Bajarin’s forecast suggests around 2m more iPhones were sold in China than North America in the quarter. He added that the launch of Apple’s new Watch in China in the coming months was likely to increase loyalty among first-time Apple customers.
“They will likely do more in China than US from here on out,” he said. “It certainly shows how important the China market is to Apple’s upside.”
While China’s mobile market is larger and growing faster than in the increasingly saturated US, Apple faces challenges there too, from new competition to run-ins with the Chinese government. The latest iPhones’ Chinese release was delayed by almost a month after a protracted regulatory review process.
China is becoming more important to Apple but that does not mean the iPhone is as significant a player there as it has been on its home turf of the US. Lower-cost devices, most using Google’s Android software, still dominate the Chinese market.
http://www.ft.com/intl/cms/s/0/4863e400-a363-11e4-bbef-00144feab7de.html#axzz3Psxn9dIO